Does route of administration affect the outcome of TNF antagonist therapy?
Open Access
- 21 June 2004
- journal article
- review article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 6 (S2) , S19-23
Abstract
The tumor necrosis factor (TNF) antagonists are parenterally administered biologic response modifiers indicated for the management of rheumatoid arthritis. Although infliximab, etanercept, and adalimumab are all members of this class, they differ in route of administration and dosing regimen. In the USA and in Europe, infliximab, in combination with oral methotrexate, is administered intravenously, initially at a dose of 3 mg/kg at weeks 0, 2, and 6, then every 8 weeks thereafter. The US Food and Drug Administration (FDA) has further approved that the dosage can be increased to 10 mg/kg and the doses can be given as often as every 4 weeks to optimize patient outcome (information based on the US package insert dated June 2002). Etanercept and adalimumab are given subcutaneously and can be self-injected. The FDA-approved dose of etanercept is 25 mg twice weekly, and of adalimumab is 40 mg every 2 weeks with methotrexate, or 40 mg alone. Medication adherence, possibly the most important factor in maintaining the benefits of anti-TNF therapy, is influenced by the interaction between the patient and his or her healthcare team, the patient's attitude toward the disease and medication regimen, and the choice of therapy.Keywords
This publication has 15 references indexed in Scilit:
- Using medications appropriately in older adults.2002
- Age-related differences in perceived asthma control in childhood: guidelines and realityEuropean Respiratory Journal, 2002
- In quest of the Holy Grail: efficacy versus effectiveness in rheumatoid arthritis.2002
- Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomesArthritis & Rheumatism, 2002
- Infliximab and Methotrexate in the Treatment of Rheumatoid ArthritisNew England Journal of Medicine, 2000
- A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Factors Associated with Medication Self Administration in Children with AsthmaClinical Pediatrics, 2000
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritisArthritis & Rheumatism, 1998
- Clinical features, diagnosis, and prognosis in rheumatoid arthritisCurrent Opinion in Rheumatology, 1993